Search

News Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis –⁠ Real-World Clinical Practice Data

The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published review summarizing retrospective, prospective, and observational studies from real-world clinical practice published in 2018–2020, the treatment duration with tofacitinib is comparable to that with biological disease-modifying drugs.

Source: Arthritis 29. 3. 2022

News Is it beneficial to combine etanercept and methotrexate in the treatment of psoriatic arthritis?

The study presented below by Canadian, American, and British authors focused on comparing the efficacy of monotherapy with methotrexate, etanercept, and their combination in patients with psoriatic arthritis.

Source: Arthritis 28. 3. 2022

News Participation in sports activities, frequency and severity of sports injuries in children with hemophilia

Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved the possibility for children to participate in various sports activities. A study conducted by Dutch authors evaluated the involvement of boys with hemophilia in sports activities and their potential link with sports injuries and bleeding.

Source: Hemophilia with Movement 28. 3. 2022

News Results of Knee and Hip Joint Arthroplasty in Hemophiliacs

Total endoprosthesis implantation represents an effective solution for the terminal stages of joint degeneration in hemophiliacs. However, compared to the general population, this group of patients exhibits certain specificities, a higher rate of complications, and historically worse surgical outcomes. Recent studies show that with advancements in surgical techniques, implants, and perioperative care, the results are approaching those of the population without a history of bleeding disorders.

Source: Hemophilia with Movement 15. 3. 2022

News Acquired Hemophilia A Newly Diagnosed in an Elderly Patient −⁠ A Case Report

At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.

Source: Acquired Hemophilia 28. 3. 2022

News PHD 2022: In the treatment of multiple myeloma we have achieved significant progress, confirm real-world data

The treatment options for multiple myeloma (MM) have significantly advanced over the past 10 years, and patient outcomes have improved. However, the most accurate guide is needed to select the right treatment modality for each particular patient among the many available options. During the Prague Hematology Days (PHD) 2022, this topic was addressed by Prof. MUDr. Roman Hájek, CSc., from the Hemato-Oncology Clinic of the Faculty of Medicine at the University of Ostrava and FN Ostrava.

Source: Hematologic Malignancies 28. 3. 2022

News Hodgkin Lymphoma in a Summary of News from Post-ASH 2021

Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT), also remotely participated in this year's Prague Hematology Days (PHD 2022). In her lecture, she presented an overview of highlights from 4 clinical studies regarding Hodgkin lymphoma (HL) presented during the Post-ASH 2021 meeting.

Source: Hematologic Malignancies 28. 3. 2022

News COVID-19 in Patients with Acquired Hemophilia A −⁠ Case Reports

At the XXVIII. Pařízek Days held in Ostrava, on the afternoon of March 17, 2022, Dr. Anna Maria Pejková from the 4th Internal Clinic of the University Hospital Hradec Králové presented 3 case reports of acquired hemophilia A.

Source: Acquired Hemophilia 29. 3. 2022

News Efficacy of L. reuteri DSM 17938 in the Treatment of Infantile Colic

Infantile colic represents a syndrome of behavioral disorders in infants characterized by episodes of uncontrollable crying, wailing, and restlessness without an identifiable cause. This is a common health issue affecting an estimated 5–40% of infants. There are no uniform criteria for the treatment of this benign condition yet, but available studies show a beneficial effect from administering probiotics containing Limosilactobacillus reuteri (previously known as Lactobacillus reuteri) compared with placebo and other treatment methods.

Source: GI, colic and microbiome 30. 3. 2022

News Clinical and Microbiological Effect of L. reuteri in the Treatment of Chronic Periodontitis

The Journal of Clinical Periodontology published the results of a study evaluating the effect of the probiotic bacterial strain Lactobacillus reuteri as an adjunctive treatment for chronic periodontitis.

Source: GI, colic and microbiome 6. 4. 2022

News Comparison of Enoxaparin and Unfractionated Heparin in Hospitalized Patients in Terms of Clinical and Cost Effectiveness

Thromboembolic disease represents one of the severe complications in hospitalized patients. Low molecular weight and unfractionated heparin are most commonly used during hospitalization as part of pharmacological thromboprophylaxis. An extensive study conducted in the United States evaluated the clinical and cost-effectiveness and safety of both therapy modalities in hospitalized patients at risk of thromboembolic disease.

Source: Thromboprophylaxis 31. 3. 2022

News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma –⁠ A Case Study

We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 4. 2022

News How to Detect COPD Early in Primary Care?

Chronic obstructive pulmonary disease (COPD) can be present even in individuals without obvious subjective symptoms, or the emerging symptoms may be overlooked by both the patient and the doctor due to their very gradual development. So, what is the path to early detection of COPD in primary care, and how can this disease be distinguished from others accompanied by similar manifestations?

Source: Treatment of Asthma and COPD 6. 4. 2022

News News in COPD Treatment Recommendations in a Nutshell

We present an overview of the most important changes in the annually updated recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Source: Treatment of Asthma and COPD 6. 4. 2022

News STADA Brings Innovative Drug for Treatment of Advanced Parkinson's Disease to Czech Republic

STADA PHARMA CZ is introducing a new system for continuous delivery of 3 active substances for the treatment of advanced stages of Parkinson's disease (PD) to the Czech market. It is one of the major innovations in the care of PD patients in the last two decades. The drug, which STADA acquired the rights to in 2020, had already been introduced in the Nordic countries where this treatment is successfully underway. In the Czech Republic, it has been fully covered since April 1, 2022.

Source: Parkinson's Disease 6. 4. 2022